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Abstract
The reconstruction or replacement of diseased heart valves, the revascularisation of coro-
nary arteries by coronary artery bypass grafting, the replacement of the central or periph-
eral blood vessels, and the reconstruction of the irreversibly damaged heart muscle 
represent the most common fields of application of cardiovascular surgery. In such cases, 
the diseased tissue is replaced by either a synthetic (metallic or polymeric) or a biological 
(xenograft, homograft, or autograft) prosthesis, or tissue engineered constructs. The aim 
of this book chapter is to give an overview over the most frequently used synthetic and 
biologic polymers as scaffold material in cardiovascular surgery.
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1. Introduction
Cardiovascular disease is the leading cause of death worldwide. In 2015 alone, 17.7 million peo-
ple died due to cardiovascular disease, accounting for 31% of all deaths worldwide [1]. Beyond 
limiting the risk factors that could potentially lead to cardiovascular disease and the adminis-
tration of a pharmaceutical regime, surgical treatment represents a life-saving option for severe 
forms of cardiovascular disease. The reconstruction or replacement of diseased heart valves, 
the revascularisation of coronary arteries by coronary artery bypass grafting, the replacement 
of the central or peripheral blood vessels, and the reconstruction of the irreversibly damaged 
heart muscle represent the most common fields of application of cardiovascular surgery. In 
such cases, the diseased tissue is replaced by either a synthetic (metallic or polymeric) or a bio-
logical (xenograft, homograft, or autograft) prosthesis, or tissue engineered constructs.
© 2017 The Author(s). Licensee InTech. This chapt r is distributed under the terms of the Creative Comm s
Attribution L cense (http://creativecommons. /licenses/by/3.0), which permits unrestricted use,
distribution, and reproduction in any medium, provided the original work is properly cited.
1.1. Limitations of currently available implants
The limitations of currently available cardiovascular prostheses necessitate further research 
and development of improved materials for diseased tissue replacement. For example, the 
implantation of synthetic prostheses, such as mechanical heart valves, requires lifelong 
anticoagulation treatment. On the other hand, glutaraldehyde-treated biological prostheses 
(xenografts) tend to calcify [2–5], whereas homograft prostheses have been reported to initi-
ate an immunogenic reaction in the recipient, which leads to rejection responses. Also, most 
implants that are in direct contact with the bloodstream show thrombogenicity [6]. Especially 
small calibre vessels are prone to stenosis due to thrombus formation, intimal hyperplasia, 
or neointima formation. Synthetic implants are very susceptible to infections, which like any 
graft failure is at the very most an indication for high-risk and expensive revision surgery [7]. 
Moreover, cardiovascular implants need to meet biomechanical requirements for appropriate 
long-term in vivo function. The development of aneurysms is not a rare case with prostheses 
in the high-pressure arterial system. Also, the characteristics of the prosthesis should support 
its integration with the surrounding tissues. Accordingly, grafts with high porosity can lead to 
good tissue integration, but high porosity could also potentially cause bleeding complications 
due to the insufficient sealing. Covering the prosthesis with anti-thrombogenic substances 
such as albumin, collagen, or gelatine predisposes to the same complication [8]. Owing to 
the ageing of the population and the subsequent need for cardiovascular implants, optimised 
materials and prostheses are necessary in the future to avoid high-risk, stressful and expen-
sive revision surgery, which induces a threatening economic pressure on healthcare systems.
1.2. Requirements for ideal cardiovascular prostheses
Based on previous experience and large-scale clinical studies with implants and the long-
term postoperative medical aftercare, there are some characteristics of an ideal cardiovascular 
prosthesis. The prosthesis should demonstrate high long-term durability and should have the 
capacity for regeneration and growth. Grafts that have the potential to regenerate would be 
especially beneficiary for the paediatric population since they would be capable of growing in 
the host, avoiding reoperations. Prosthetic vessels and valves should also present physiologi-
cal hemodynamics, allow for unrestricted blood flow without any volume losses, turbulences, 
or stasis, and present no thrombogenicity [9] or interference with the blood constituents [10]. 
Since anticoagulation or platelet inhibition therapy might lead to bleeding complications, 
these therapeutic regimes should be avoided [11]. Furthermore, there should be no interfer-
ence with other cardiac structures [12, 13]. In case of in vitro–seeded prostheses, the utilised 
cells need to be non-immunogenic (autologous or HLA-silenced homologous) and functional. 
Homologous donor cells in homografts can cause immunogenic reactions and subsequent 
graft degeneration, scar tissue formation, loss of flexibility, and, ultimately, graft rejection 
[14]. Moreover, any degradation products of the implanted prosthesis should be non-toxic 
and metabolise physiologically [15, 16]. Preferably, the ideal prosthesis should also possess 
a physiological structure, resembling the tissue it replaces [17, 18]. The prosthesis should be 
available for all patients in need, easily storable, transportable, and implantable.
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1.3. Tissue engineering of regenerative grafts
Tissue engineering allows for the development of viable implants, with a regenerative and 
growth potential after implantation in the patient. The fundamental approach of tissue engi-
neering comprises five steps [19, 20] (Figure 1):
A. Cell sourcing, cultivation, and expansion in vitro.
B. Development of a scaffold of either synthetic or biological origin (e.g. collagen or decel-
lularised tissue), which could either be implanted for subsequent endogenous cell re-
population (in vivo tissue engineering) or seeded with appropriate cells in vitro prior to 
implantation (in vitro tissue engineering).
C. Cell seeding of the scaffold in vitro, followed by physical conditioning and maturation 
(regeneration and neo-tissue formation) in a functional simulation system (bioreactor).
D. Implantation of the scaffold or the tissue-engineered construct.
E. In vivo remodelling of the graft (guided tissue engineering).
Scaffolds should contain as many physiological characteristics of the natural extracellular 
matrix (ECM) as possible, including histoarchitecture and composition. Numerous complex 
interactions between the ECM and cells are necessary for inducing appropriate cellular func-
tion, including adhesion, migration, proliferation, and differentiation, as well as ECM degra-
dation and synthesis [21–25]. The closer the scaffold’s substrate for cell seeding is to its natural 
equivalent, the more the seeded cells develop their physiologic phenotype [26] to produce a 
viable, metabolically active prosthesis. Mainly interstitial cells and endothelial cells are used 
in cardiovascular tissue engineering. Seeding with endothelial cells (ECs) fulfils two main 
functions especially for cardiovascular tissue–engineered constructs; the scaffold is a foreign 
body and, therefore, a target not only for thrombocytes but also for immune cells. An EC layer 
shields the scaffold material and reduces both thrombogenicity and immunogenicity, the lat-
ter being the reason for the prostheses’ degradation.
Mimicking natural ECM synthesis and degradation processes, the scaffold of the tissue-engi-
neered construct would be degraded and regenerated by the seeded connective tissue cells. 
To maintain structural and mechanic integrity, the degradation rate of the scaffold should 
match the formation of new tissue [27]. Because of these remodelling, the tissue-engineered 
prosthesis would not be indistinguishable from the native organ after a while.
Decellularised xenogeneic or allogeneic tissue ECMs or polymers are commonly utilised sub-
strates for engineering of cardiovascular scaffolds. The main drawbacks of xenogeneic or allo-
geneic tissue ECMs are the potential risk of disease transmission, variability in production, 
and limited availability (allogeneic) [28]. On the other hand, polymers made of biological or 
synthetic substances can be produced in unlimited amounts under sterile conditions. The aim 
of this chapter is to give an overview of polymer-based synthetic or biologic cardiovascular 
prosthesis.
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2. Indications for the use of polymer-based cardiovascular implants
2.1. Aetiology, pathophysiology, and surgical therapy of heart valve disease
There is a huge diversity of aetiologies of heart valve defects requiring surgical intervention. 
Table 1 gives an overview of heart valve diseases requiring surgical intervention. Tricuspid or 
pulmonary valve dysfunction has a lower incidence than pathologies of the aortic or mitral valve 
[29, 30] since the left heart bears higher blood pressures and the valves are, therefore, subjected to 
a higher grade of mechanical stress. In general, heart valve dysfunction involves  regurgitation, 
Figure 1. Drawing of the principles of tissue engineering. A: Cell sourcing, cultivation, and expansion in vitro. 
B: Development of a synthetic or biological scaffold. C: Cell seeding of the scaffold in vitro. D: Implantation of the 
scaffold. E: In vivo remdelling of the graft.
Scaffolds in Tissue Engineering - Materials, Technologies and Clinical Applications270
stenosis, or a combination of both. Left untreated, valvular dysfunction, which initiates either 
a concentric (stenosis) or an eccentric (regurgitation) hypertrophy, results in congestive heart 
failure—a considerable economic burden and the most common reason for hospitalization of 
the elderly [31]. Since the early days of valve replacement, the procedure is being carried out 
by applying either mechanical (Figure 2A) or biological (Figure 2B) prostheses, the latter being 
xenogeneic (made from treated animal valves or animal-derived pericardium) or allogeneic.
There are different access paths and principles to implant heart valve prostheses. Since the 
1960’s, the standard surgical approach, via full sternotomy, is the therapy of choice for most 
patients. In surgery of the elderly and severely co-morbid patients, it is beneficial to reduce the 
time of the intervention to a minimum, which can be achieved by implanting sutureless heart 
valve prostheses (Figure 2C). In contrast to the standard surgical approach, these valves do not 
require the time-consuming suturing of the valve into the annulus, as those grafts keep their 
position by an expandable metal stent. The third approach is the percutaneous, catheter-based 
application of a heart valve transcatheter aortic valve implantation (TAVI). This intervention 
is performed in the operating room, cardiac catheter laboratory, or hybrid operating room 
(Figure 2D). Innovative materials for polymer-based valve prostheses, the aforementioned 
different procedures, and the resulting options and restrictions should always be considered.
2.2. Aetiology, pathophysiology, and surgical therapy of vascular disease
Arteriosclerosis is an arterial disease, in which the lumen of the vessel is occluded by calcifica-
tion [32]. In case of a complete obstruction, the area perfused by the affected artery undergoes 
critical hypoperfusion. A complete acute obstruction of the vessels leads to myocardial infarc-
tion, apoplexy, or insufficient blood circulation in the extremities. An overview of the aetiol-
ogy of aortic disease with the need for interventions is presented in Table 2. The ischemic 
cardiovascular disease carries the highest mortality rate worldwide [1]. The gold standard for 
the treatment of severe cases of occlusive vascular disease is surgical revascularisation. In these 
cases, the affected vessels are replaced, or the obstruction is bridged by a vascular graft (i.e. 
“bypass-surgery”). Synthetic polymer grafts made from alloplastic materials, such as Dacron, 
Congenital Immunological Infectious Degenerative Traumatic Others
• Prolapse
• Aortic aneurysm
• Bicuspid valves
• Primary 
cardiomyopathy
• Stenosis
• Atresia
• Regurgitation
• Marfan 
syndrome
• Ehlers-Danlos 
syndrome
• Rheumatic 
fever
• Scarlet fever
• SLE
• Scleroderma
• Endocarditis
• Endomyocarditis
• Prolapse of 
mitral valve
• Calcification
• Aortic 
dissection
• Aortectasis
• Blunt 
thoracic 
trauma
• Ischemia
• Mechanic 
(HOCM)
• Idiopathic
Table 1. Overview of heart valve diseases with the potential need for surgery (mitral- and aortic valve).
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are routinely used clinically for the replacement of large vessels, such as the aorta (Figure 3). 
However, synthetic polymer grafts for small vessels still show problems regarding patency 
and development of an intimal hyperplasia or thromboembolic events [6]. Furthermore, a life-
threatening adverse effect of long-distance replacement of large vessels is therapy-refractory 
hypertension with subsequent end-organ damage, since the currently available aortic grafts 
lack the function of Windkessel. Owing to this, the identification of suitable, anti-proliferative, 
regenerative, and mechanically functional materials, manufacturing processes, and coatings 
still are the primary objectives of current research in the field of vascular prostheses.
2.3. Aetiology, pathophysiology, and surgical therapy of myocardial disease
Ischemic heart conditions, such as chronic coronary artery disease, myocardial infarction or 
infection, or immunologic diseases such as sarcoidosis or amyloidosis, lead to a loss of viable 
heart muscle cells (cardiomyocytes). In contrast to other cells, adult human cardiomyocytes can-
not proliferate. Therefore, the necrotic myocardium is replaced by functionless scar tissue. This 
weakens the heart muscle pump and eventually causes heart failure. The heart is not able to gen-
erate an adequate blood flow. Congestive heart failure is characterised by a high mortality and 
recurrent, long hospitalisations [33]. In 2013, congestive heart failure was the reason for every 
Figure 2. Currently used valve prostheses: (A) mechanical valve, (B) biological, xenogenic valve, (C) sutureless, biological 
valve, and (D) valve for TAVI procedure.
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Deformation Occlusive diseases Aneurysm Trauma Others
• Aneurysm • Arteriosclerosis • Arteriosclerosis • Blunt thoracic trauma • Aortic insufficiency
• Aortic 
coarctation
• Stenosis • Familial thoracic 
aortic aneurysm
• Penetrating wounds • Shunts (dialysis)
• Aortic arch 
abnormalities
• Thrombosis 
(acute vs. 
chronic)
• Marfan 
syndrome
• Iatrogenic trauma
• Aberration • Embolism • Trauma • erosion 
(tracheostomy)
• Stenosis • AV fistula
• Inflammatory 
(e.g. SLE)
• Infection (e.g. 
rheumatic fever)
• Iatrogenic (e.g. 
puncture)
• Pregnancy
Table 2. Overview of large vessel diseases with the potential need for surgery.
Figure 3. Operative situs of aortic surgery: (A) severe aneurysm of the ascending aorta and (B) aortic prostheses made of 
Dacron following surgical replacement of the dilated segment.
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third death in Germany [34], producing a cost of 3.2 billion Euro [35]. The mortality of conges-
tive heart failure has been reported to reach rates up to 36% per year. In addition to pharmaco-
logical therapy, there are surgical options for the treatment of end-stage heart failure, including 
heart transplantation, implantation of ventricular assist devices, or myocardial reconstruction 
(Dor procedure) [36]. In a ventriculoplasty, non-functional, dilated tissue is resected and the 
physiologic geometry and size of the heart chamber are reconstructed utilising a repair patch. 
For this purpose, a large variety of patch materials and biologic substrates have been assessed.
3. Polymers as a substrate in engineering innovative cardiovascular 
prostheses
Although the first work on polymeric heart valves goes back to the late 1950s [37–39], poly-
meric heart valves are not implanted in patients on a regular basis, since they have not yet 
shown satisfactory results. Depending on the type of polymer, the main issues with polymeric 
heart valves were low durability due to the tendency to become stiff with subsequently regur-
gitation or even complete shredding of the leaflets [40], poor long-term survival and a high 
mortality rate due to perioperative complications [41, 42], and thrombotic and calcific degen-
eration of the valve leaflets, leading to severe complications (thromboembolic events with 
end-organ damage, regurgitation, and heart failure) [43]. Thus, extensive research has been 
done on different polymers. Although there are many ways to classify polymeric scaffolds, 
the materials used to develop heart valve scaffolds can be classified as natural or synthetic. 
Examples of synthetic polymers include polycaprolactone (PCL), polytetrafluoroethylene 
(PTFE), polyethylene glycol (PEG), and polyurethanes (PU) [44–46], whereas examples of 
natural materials include, amongst others, hyaluronic acid, fibrin and collagen [47–51], and 
the combination of them [52].
The major drawbacks of natural polymers are their poor mechanical properties and fast 
degradation rate. Several studies have reported on mixing natural polymers with biologic 
and synthetic materials to combine the high biocompatibility of the natural polymers with 
the increased mechanical properties of the co-material with encouraging results [53–55]. For 
example, Stamm et al. used enzymatically decellularised porcine aortic valves and impreg-
nated them with biodegradable polyhydroxybutyrate, since decellularisation leads to the 
exposure of the ECM collagen and by that to a high thrombogenicity. In that study, impreg-
nating the valves with polyhydroxybutyrate had two positive effects: (a) the collagen matrix 
was covered and, therefore, was no longer thrombogenic and (b) the biomechanical proper-
ties of the valve were improved since decellularisation using enzymatic digestion weakened 
the mechanical properties of the valve. In large animal testing, the aforementioned valves 
functioned well for up to three months and partially developed the morphological character-
istics of the native aortic valve [56].
The work of Stamm et al. is a good example for the feasibility of implanting polymeric scaf-
folds in vivo. However, the implantation of these valves is still not an option in the clinical 
setting. On the one hand, the lack of long-term results by means of safety and effectiveness, in 
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comparison to regularly implanted valves, does not allow for clinical use; only long-term in 
vivo studies can reveal, for example, the toxicity and side effects of degradation products. On 
the other hand, a major hurdle for the clinical use is calcific degeneration. Although tissue-
engineered polymer-based heart valves show a lower tendency to calcify in vivo compared to 
standard bioprostheses, there is again a lack of long-term clinical studies, since the standardly 
used sheep model is less thrombogenic than the human coagulation system. Experience with 
the utilisation and application of the most frequently used synthetic and natural polymers as 
graft material will be introduced below. An overview of the pros and cons of these polymers 
is given in Table 3.
3.1. Polycaprolactone-based polymers (PCL)
Thermoplastics based on polycaprolactone have been largely used in biomedical applica-
tions, as they show excellent biocompatibility and a controlled biodegradation. Examples of 
these types of polymers are polylactide (PLA) or polyglycolide (PGA), which are used in a 
mixture with other natural or synthetic materials, or alone. Both PLA and PGA are classi-
fied as biocompatible and non-toxic and are FDA-approved for human implantation [57, 58]. 
Degradation of these polymers in vivo is facilitated through a hydrolytic splitting of the ester 
bonds that leads to the formation of the natural metabolite lactic acid and glycolic acid. The 
risk for acidosis through local accumulation of these degradation products is low [59]. Owing 
to the presence of the additional methyl group, PLA is more hydrophobic than PGA and has 
Polymer Pros Cons References
Synthetic polymers
Polycaprolactone Excellent biocompatibility, 
controlled biodegradation
High stiffness, limited ability 
for cell adhesion
[57, 58, 61, 62]
Polyhydroxyalkanoate High flexibility, occurs 
naturally, thermoplasticity
High production costs [66–69]
Polyurethane Resistant to degradation, high 
durability
Limited biocompatibility [75, 76]
Polyglycerol sebacate Low stiffness, high elastic 
properties
Low porosity, poor cell 
adhesion
[82–84]
Polyethylene glycol Good mechanical properties, 
potential for functionalization
Poor cell adhesion [98]
Biological polymers
Collagen High biocompatibility, low 
immunogenicity
Very high thrombogenicity, 
poor mechanical properties
[106–108]
Fibrin High biocompatibility, low 
immunogenicity, easily derived
Poor mechanical characteristics [48, 112]
Hyaluronic acid High biocompatibility, low 
immunogenicity
Poor mechanical characteristics [104, 118]
Table 3. Overview of pros and cons of most frequently used synthetic and natural polymers.
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a lower degradation rate; while PGA is generally completely degraded in 2–3 months, the 
degradation of PLA in its preferred metabolic D-configuration takes an average 2 years [57]. A 
possibility for the regulation of the degradation rate is the copolymerization of PLA with PGA 
[60]. However, PCL scaffolds have a high stiffness and have a limited ability for cell adhesion 
and proliferation [61, 62]. Hence, the production of hybrid compound scaffolds is only indi-
cated for myocardial grafts, vascular prostheses, and bioartificial heart valves.
Shinoka et al. used a scaffold made of a PLA mesh between two layers of randomly orientated 
PGA fibres and seeded it in vitro with ovine fibroblasts, smooth muscle cells (SMCs), and ECs. 
The autologous implantation as a replacement of the posterior leaflet of the pulmonary valve 
showed an adequate functionality, although the flexibility was reduced in comparison to the 
native leaflet. Furthermore, the cellular architecture and synthesis of collagen were indicative 
of a delicate expression of ECM [63]. Sodian et al. reported on the production of a tricuspid 
heart valve made of a PGA structure that unfortunately demonstrated insufficient structural 
integrity under physiological flow and pressure conditions [64]. To improve both the plastic-
ity and mechanical properties, Hoerstrup et al. coated the fibre structure above with poly-
4-hydroxybutyrate, which resulted in a thermoplastically editable composite [65].
3.2. Polyhydroxyalkanoate (PHA)
Linear polyesters of hydroxy fatty acids are generally pooled as polyhydroxyalkanoates. 
PHAs show a high biocompatibility and occur naturally as reserve substances in a variety 
of bacteria [66, 67]. The widespread use as scaffold materials in valvular tissue engineering, 
in combination with other materials, or as a standalone substrate is due to their higher flex-
ibility in comparison to PLA and PGA, as well as their thermoplasticity, which allows for 
moulding with different thermal procedures [68, 69]. The degradation rates, besides the spe-
cific molecular weight, are dependent on their crystallinity [70]. Thus, poly-4-hydroxybutyric 
acid degrades rather fast in vivo [71], whereas polyhydroxyoctanoate is still detectable after 
24 weeks [72]. The mechanism of degradation is based on a hydrolytic splitting of ester bonds 
and distinguishes through a delayed loss of mass, as the loose chain fragments only start to 
diffuse at a certain length [16]. Furthermore, it is expected that these degradation products 
are non-toxic and show a lower acidity compared to PLA [67, 73]. Sodian et al. seeded ovine 
vascular cells onto a tricuspid heart valve scaffold made of porous polyhydroxyoctanoate 
and implanted it in autologous pulmonary position. After 17 weeks, the collagen content was 
above the reference value of native tissue, whereas after explantation, the valves showed a 
characteristic non-linear stress-strain behaviour. Although there was no confluent endothe-
lium on the grafts’ surface, there was no sign of material-induced thrombogenicity [74].
3.3. Polyurethane (PU)
Polyurethanes are polymers of organic units joined by carbamate links and similar to PCL-
based polymers; they are widely used in biomedical applications. PUs show a good long-
term durability since they are resistant to degradation. However, modifications of the original 
structure of PUs have been conducted to allow for a controlled biodegradation, mechanical 
stability, and improved cell colonisation in PU-based heart valve prostheses, vascular grafts, 
and myocardial patches [75, 76]. PUs often were used in combination with other materials or 
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as an unblended polymer. Scaffolds made of PU are a promising option for tissue engineer-
ing of myocardial replacement tissue, especially after seeding with mesenchymal cells [77] 
and in combination with other polymers for improving cell adhesion, porosity, and mechanic 
stability [78]. Fromstein et al. seeded PU scaffolds with embryonic stem cells in a bioreactor 
and investigated the effect of the macro-architecture on the adhesion, viability, and morphol-
ogy on the seeded cells [79]. The authors found cells with the typical morphology of cultured 
cardiomyocytes on electrospun fibrous scaffolds, whereas there were no cardiomyocyte-like 
cells on scaffolds made through thermally induced phase separation (TIPS).
In vascular prostheses, McCarthy et al. investigated PGA, PLA, PCL, and PU as supportive 
materials of the elastica interna of a decellularised murine aorta [55]. The developed grafts 
were comparable to the native saphenous vein regarding burst pressure and wall diameter. 
In a direct comparison of their hybrid grafts, polyurethane grafts showed better burst pres-
sure and tensile properties than the other polymeric scaffolds. Furthermore, Nieponice et al. 
reported that in vitro seeding of the PU grafts with muscular stem cells improved stability 
and functionality [80]. The authors implanted seeded and non-seeded grafts in the aortic posi-
tion of a rat model and found a substantial lower graft failure in the cell-seeded group. In 
developing vascular prostheses, not only the superior mechanical properties of the polyure-
thane grafts should be pursued, but also the potential neointima formation and graft stenosis 
should be considered in the production of these grafts, which could be addressed with drug 
release mechanisms [81].
3.4. Polyglycerol sebacate (PGS)
Firstly produced in 2002 by a polycondensation reaction of glycerol sebacic acid, PGS has 
been widely studied in the context of biomedical applications. Owing to the low stiffness and 
high elastic properties, PGS has been reported to be a promising scaffold material for tissue 
engineering [82–84]. Depending on the production parameters and structural conditions, the 
elastic modulus of PGS can vary between 0.025 and 12 MPa, which corresponds to the modu-
lus of human myocardial tissue [85]. The mechanical properties can be altered by adjusting 
the duration of the cross-linking and the concentration of the educts, which have been FDA-
approved regarding their biocompatibility [84]. To improve the mechanical properties, Xu 
et al. combined PGS with PLA, and they reported a stiffness that was comparable to the native 
myocardial tissue [86].
One major challenge in the production of PGS-based scaffolds is the fabrication of a porous 
structure [87]. To face this challenge, Masoumi et al. used laser ablation to produce a diamond-
shaped porous microstructure [88]. Sant et al. produced a fibrous scaffold using electrospin-
ning; however, they needed to adapt the viscosity of the fluid by adding polycaprolactone. 
Following the seeding of these scaffolds with human valvular intermediate cells (VICs), the 
authors found a high cell viability, as well as the expression of a dense collagen network [27]. 
Jeffries et al. compared electrospun fibrous PGS matrices to porous PGS foam and found a 
fivefold higher torque strength and better suture retention of the former [89]. The porosity of 
the PGS scaffolds is crucial for in vitro and in vivo cell seeding [90], as well as for mechanical sta-
bility. This is of particular importance in the development of cardiac patches and myocardial 
prostheses since these grafts need to have a reliable mechanical integrity, which normally is 
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achieved by increasing the wall thickness of synthetic grafts. However, the increase of the wall 
thickness limits oxygen supply by diffusion to the seeded cells, posing the need for vasculari-
sation. Therefore, PGS grafts are produced with a high porosity to mimic native vascularisa-
tion [90, 91]. Furthermore, cell adhesion can be improved by simulating epitope sequences 
of laminin and fibronectin through connecting specific amino acid sequences with the PGS 
scaffolds [92].
In an in vitro haemocompatibility study with human blood, PGS showed a lower adhesion 
of thrombocytes and release of inflammation markers, compared to polytetrafluoroethyl-
ene, which is indicative of improved haemocompatibility [93]. Guler et al. investigated the 
ECM of decellularised sheep aorta connected to PGS in situ and showed that there was no 
additional impairment on the smooth muscle cells of a human aorta [94]. In this fashion, 
Guler et al. augmented the regenerative potential of allogeneic prostheses with the superior 
mechanical properties of PGS elastomers. To investigate in vivo degeneration, Pomerantseva 
et al. implanted disc-shaped PGS samples subcutaneously in rats, which only generated a 
minor tissue reaction. They reported a superficial degradation process by enzyme-mediated 
hydrolytic splitting of ester bonds [83]. The PGS samples were maintained in vivo for several 
weeks and were characterised by a linear loss of mass [83, 95]. The degradation products 
were glycerine and a metabolic intermediate of the ω-oxidation (sebacic acid) [84]. Moreover, 
Stuckey et al. implanted myocardial PGS patches in rodent hearts. They found a significant 
faster degeneration than in previous in vitro experiments [96]. Khosravi et al. have found 
aneurysms after infrarenal implantation of aortic grafts made from electrospun PGS [54]. The 
authors suggested that the reason of the aneurysms was the suspected degradation of the PGS 
without a sufficient remodelling process simultaneously. However, there was no aortic dis-
section, since the grafts were covered with a thin PCL layer. In contrast to these findings, Wu 
et al. reported on an early remodelling process after implantation of a heparin-covered PGA 
graft in the abdominal aortic position [97].
3.5. Polyethylene glycol (PEG)
PEG is a hydrophilic polyether bond of the divalent alcohol ethylene glycol, which is neither 
toxic nor immunogenic and FDA-approved for implantation in humans. Also, it has been used 
on a regular basis in the field of tissue engineering [98] due to its potential for functionalisation 
of the terminal hydroxyl groups by means of an adaption for cell adhesion and degradation, 
as well as its mechanical properties [98]. For example, a hydrolytically degradable copolymer 
results from an integration of PLA or PGA into the polyether structure [99]. Benton et al. 
cross-linked the PEG chains with peptide sequences, which contained a proteolytic sensitiv-
ity towards matrix metalloproteinases, therefore, allowing for a cell-controlled degradation. 
Also, a specific amino acid sequence (arginine-glycine-asparagine) was integrated into the 
hydrogel matrix. The encapsulated porcine VICs showed an increasing elongated morphol-
ogy, as well as an improved occurrence of integrin binding as a sign for increased cell adhe-
sion [100]. Moreover, porcine VICs cultivated in a copolymer of methacrylised hyaluronic 
acid and PEG molecules produced both collagen and elastin [101]. Hockaday et al. combined 
photopolymerisation of PEG with 3D printing and reproduced an  anatomically precise aortic 
valve [102]. Zhang et al., however, produced an anisotropic scaffold structure by using an 
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aperture that allowed for local varying light irradiation and, subsequently, a varying grade 
of cross-linking [103].
3.6. Collagen
Collagen is the most prevalent structure protein of the human body and is also a substantial 
component of the valvular extracellular matrix [104, 105]. Subsequently, collagen is highly 
biocompatible and shows only low immunogenicity [106]. Moreover, the specific peptide 
sequences promote cell adhesion, which could drive the cellular population of collagenous 
matrices [107]. However, the conventional isolation from animal tissue bears the risk of zoo-
nosis [108]. Furthermore, collagen has a high thrombogenic potential [109]. Therefore, its use 
in the engineering of tissues with contact to the blood flow requires coating or masking of the 
surface. This is often realised by endothelialisation [104].
Further limitations of collagen-derived hydrogels as a scaffold material are its poor mechani-
cal properties in comparison to native valve tissue as well as the rapid and hardly predictable 
degradation process in vivo [104, 106]. The degradation happens enzymatically through col-
lagenases [110]. The degradation rate varies depending on the implantation site [109]. Cross-
linking of peptide chains may improve the stability and influence the degradation rate [98]. 
For this, both chemical agents (glutaraldehyde and formaldehyde) and physical procedures 
(UV radiation and heat treatment), as well as insertion of polymers, are applied [110].
To improve the compressive strength, Flanagan et al. integrated chondroitin sulphate into a 
collagen matrix and subsequently seeded it with porcine VIC and valvular endothelial cells 
(VEC). During the total cultivation time of 28 days, the cells were mitotic active and kept 
their initial phenotype. Histochemical examination showed both collagen synthesis and, most 
likely because of chondroitin sulphate, the production of elastin. Nevertheless, they observed 
a significant contraction of the matrix through cellular interaction [111], which was in line 
with the findings of Benton et al. who also reported on halving the initial matrix dimension 
due to contraction in in vitro studies [100].
3.7. Fibrin
Fibrin represents the fundamental substrate for ubiquitous tissue repair mechanisms and, 
therefore, is a natural scaffold material, whose precursors are relatively easy and can be 
derived from the patients’ blood plasma. Thus, allogenic and autologous scaffolds can be gen-
erated by fibrin, which contains only a low risk of a graft-versus-host disease. The degrada-
tion products also stimulate the production of extracellular matrix angiogenesis [112]. Hence, 
fibrin displays favourable properties for tissue engineering of cardiovascular scaffolds. On 
the other hand, cardiovascular implants are in direct contact with the bloodstream and its 
inherent lytic enzymes such as plasmin, which may rapidly degrade fibrin [48].
In a study done by Ye et al. fibrinolysis was not evident at a concentration of fibrin at a level 
of 20 μg/ml in a surrounding culture medium, whereas the fibrin hydrogel degraded in two 
days without adding the plasmin antagonist aprotinin. The modified-release degradation also 
led to an increased collagen expression in human myofibroblasts [113]. However, the cellular 
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production of collagen fibres led to a contraction of the fibrin matrix. Jockenhövel et al. inhib-
ited the contraction through fixation of the fibrin scaffold margin with a poly-l-lysine-solu-
tion [48]. They also introduced an injection moulding process to produce and to seed cardiac 
valve–shaped scaffolds. The polymerisation of fibrin took place in a mould and was triggered 
by a gradual injection of a fibrin solution into a thrombin-containing cell suspension. The 
produced fibrin gel showed a homogenous distribution of cells [48]. Robinson et al. set up a 
mould, in which the fibrin matrix compacted in a determined direction. In this way, an aniso-
tropic collagen expression similar to a native heart valve’s configuration was initiated [114].
However, the mechanical stability of fibrin-based scaffolds is not sufficient to withstand the 
hemodynamic loads of the high-pressure zones of a human circulation. Flanagan et al. per-
formed a pulsatile preconditioning of fibrin-based heart valve prostheses to face this problem 
and achieved an improved synthesis of extracellular matrix with a subsequently higher stability 
of the fibrin structure [115].
After that, they populated a cardiac valve scaffold with fibroblasts, smooth muscle cells, and 
endothelial cells of an ovine carotid artery for 28 days. They implanted this preconditioned, 
autologous scaffold into pulmonary valve position. Three months following implantation, 
the scaffolds showed a biological tissue-like consistency as well as a functional endothe-
lium, whereas no fibrin could be detected in the grafts anymore. However, the remodelling 
led to a contraction of the leaflets with a subsequent valve insufficiency [50].
Keeping up the structural integrity of fibrin-based scaffolds was of lesser importance in a 
study by Chi et al. They seeded a fibrin–hyaluronic acid matrix with bone marrow mesenchy-
mal stem cells and used the patches in a rat infarction model [116]. However, the patch was 
not used as a prosthesis, but as a vehicle to deposit stem cells in the infarction area.
For the production of fibrin-based vessel prostheses, Aper et al. condensed blood-derived 
fibrin by centrifugation [117]. The resulting cross-linking of the fibrin fibres led to a higher 
mechanical stability of the vessel segments up to a pressure of 230 mmHg. Six months after 
the replacement of carotid arteries of sheep, the authors reported on an almost complete phys-
iologic remodelling of the grafts.
3.8. Hyaluronic acid
Hyaluronic acid is an unsulphated glycosaminoglycan, whose repetitive disaccharide units 
consist of d-glucuronic acid and n-acetylglucosamine. Hyaluronic acid occurs in mammals 
mainly as an extracellular part of the connective tissue, has a water-binding as well as a tex-
ture-priming function [118], and is to be found in large extent in heart valve tissue (up to 
50% of the glycosaminoglycan content) [104]. Hyaluronic acid is also an essential component 
of the embryonic development of the heart [119]. Furthermore, the immunogenic potential 
of commercially available hyaluronic acid (mainly made from bacterial fermentation) is low 
due to the cross-species structural homology [120]. Finally, the presence of hyaluronic acid 
promotes the expression of extracellular matrix proteins: VIC cultivated on a hyaluronic acid 
coated surface produced significantly higher amounts of ECM proteins than VIC on uncoated 
polystyrene [49].
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However, the weak mechanical properties of hyaluronic acid and the high in vivo degradation 
rate advise against its utilisation in tissue engineering of cardiovascular scaffolds [118]. The 
process of degradation is based on the enzyme hyaluronidase, and its half-life period lasts 
from several hours up to a few days as a function of the local enzyme concentration.
To manufacture a hydrogel employable as a scaffold for cardiovascular prostheses, cross-
linking of hyaluronic acid is possible. For this purpose, methacrylation is an often used 
tool [121]. The resulting methyl acrylate hyaluronic acid is photo–cross-linkable, whereby 
the mild conditions of a photopolymerisation allow for the encapsulation of cells into the 
manufactured hydrogel [119]. Hyaluronan benzyl ester can be processed in manifold ways 
to serve as an appropriate substrate for tissue engineering [122]. By seeding neonatal rat 
cardiomyocytes on knitted hyaluronan benzyl ester, Boublik et al. produced hybrid myo-
cardial prostheses with sufficient mechanical properties for an in vivo implantation in a rat 
model [123].
4. Conclusions
Currently, no optimal polymer for manufacturing an ideal cardiovascular prosthesis has been 
identified yet. There are rather specific requirements, such as functionality, biocompatibility, 
and regenerative potential to be taken into account while selecting a substrate for a particu-
lar application, implantation site, and host species. Beyond promising synthetic and biologic 
elastomers, their combination with natural, cell-free matrices can be employed to develop car-
diovascular scaffolds as well. However, the huge variety of the currently available materials, 
coatings, and manufacturing processes, the differences of investigation techniques in vitro 
and in vivo, as well as the inconsistent selection of evaluation criteria and test parameters 
impede the comparability of the currently conducted investigations. Consistent analytical 
standards would facilitate a clear, valid, and comparable perspective on polymer research 
and thereby would increasingly lead to a faster translation of this important field of research 
into clinical reality.
The current overview of developments in the investigation of cardiovascular implants war-
rants the hope for innovative grafts, which are manufactured according to the principles of 
tissue engineering and which can be used clinically to make sustainable and regenerative 
therapies available for all patients in the future.
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